Article
Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
The Lancet. Respiratory medicine - 1 Sept 2017
Yang Jin-Ji, Zhou Caicun, Huang Yisheng, Feng Jifeng, Lu Sun, Song Yong, Huang Cheng, Wu Gang, Zhang Li, Cheng Ying, Hu Chengping, Chen Gongyan, Zhang Li, Liu Xiaoqing, Yan Hong Hong, Tan Fen Lai, Zhong Wenzhao, Wu Yi-Long
Abstract excerpt
BACKGROUND: For patients with non-small-cell lung cancer (NSCLC) and multiple brain metastases, whole-brain irradiation (WBI) is a standard-of-care treatment, but its effects on neurocognition are complex and concerning. We compared the efficacy of an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), icotinib, versus WBI with or without chemotherapy in a phase 3 trial of patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.